Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

The future of psychopharmacology of depression.

Chang T, Fava M.

J Clin Psychiatry. 2010 Aug;71(8):971-5. doi: 10.4088/JCP.10m06223blu. Review.

PMID:
20797377
2.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
3.

Pharmacotherapy of early-onset depression. Update and new directions.

Martin A, Kaufman J, Charney D.

Child Adolesc Psychiatr Clin N Am. 2000 Jan;9(1):135-57. Review.

PMID:
10674194
4.

Dopaminergic-based pharmacotherapies for depression.

Papakostas GI.

Eur Neuropsychopharmacol. 2006 Aug;16(6):391-402. Epub 2006 Jan 18. Review.

PMID:
16413172
5.

Emerging drugs for major depressive disorder.

Connolly KR, Thase ME.

Expert Opin Emerg Drugs. 2012 Mar;17(1):105-26. doi: 10.1517/14728214.2012.660146. Epub 2012 Feb 20. Review.

PMID:
22339643
6.

Nonsomatic treatment of depression.

Sherrill JT, Kovacs M.

Child Adolesc Psychiatr Clin N Am. 2002 Jul;11(3):579-93. Review.

PMID:
12222084
7.

The efficacy, tolerability, and safety of contemporary antidepressants.

Papakostas GI.

J Clin Psychiatry. 2010;71 Suppl E1:e03. doi: 10.4088/JCP.9058se1c.03gry.

PMID:
20371030
8.

Emerging treatments for major depression.

Norman TR, Burrows GD.

Expert Rev Neurother. 2007 Feb;7(2):203-13. Review.

PMID:
17286553
9.

[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].

Gourion D.

Encephale. 2008 Jan;34(1):73-81. doi: 10.1016/j.encep.2007.12.001. Epub 2008 Feb 5. Review. French.

PMID:
18514154
10.

Major depressive disorder treatment guidelines in America and Europe.

Davidson JR.

J Clin Psychiatry. 2010;71 Suppl E1:e04. doi: 10.4088/JCP.9058se1c.04gry.

PMID:
20371031
11.

Differences in mechanism of action between current and future antidepressants.

Stahl SM, Grady MM.

J Clin Psychiatry. 2003;64 Suppl 13:13-7. Review.

PMID:
14552651
12.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
13.

Moclobemide: therapeutic use and clinical studies.

Bonnet U.

CNS Drug Rev. 2003 Spring;9(1):97-140. Review.

14.

Problems with currently available antidepressants.

Gumnick JF, Nemeroff CB.

J Clin Psychiatry. 2000;61 Suppl 10:5-15. Review.

PMID:
10910012
15.

Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder.

Papakostas GI.

J Clin Psychiatry. 2009;70 Suppl 6:16-25. doi: 10.4088/JCP.8133su1c.03. Review.

PMID:
19922740
16.

Psychiatric ethics and emerging issues of psychopharmacology in the treatment of depression.

Cohan JA.

J Contemp Health Law Policy. 2003 Winter;20(1):115-72. Review. No abstract available.

PMID:
15067929
17.

[Domino principle--monoamines in bottom-view].

Sümegi A.

Neuropsychopharmacol Hung. 2008 Jun;10(3):131-40. Review. Hungarian. Erratum in: Neuropsychopharmacol Hung. 2009 Sep;11(3):149.

18.
19.

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

Kasper S, Hamon M.

World J Biol Psychiatry. 2009;10(2):117-26. doi: 10.1080/15622970902717024. Review.

PMID:
19255935
20.

Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression.

Ghaemi SN.

Bipolar Disord. 2008 Dec;10(8):957-68. doi: 10.1111/j.1399-5618.2008.00639.x. Review.

PMID:
19594510
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk